San Diego-based Tocagen Inc. announced Wayne Saville has been named vice president of clinical development and Mary Rose Keller has been named vice president of clinical operations.

"We are expanding our clinical team with individuals who have deep experience in drug development, regulatory approval, launch and commercialization activities," said Jamey Skillings, chief medical officer of Tocagen. "Wayne and Mary Rose bring decades of valuable expertise in clinical development and medical affairs at a pivotal time for Tocagen."

Saville has more than a decade of experience in clinical development and medical affairs for cancer products. Prior to joining Tocagen, he headed medical affairs at Genoptix, an oncology diagnostics laboratory acquired by Novartis. Previous to that position he was a director of clinical research at Amgen, where he led late-stage development of a cancer drug.

Keller has more than two decades of experience in drug development and clinical operations, and has worked with numerous research-focused organizations while at University of California, San Francisco's Cancer Research Institute, including the Brain Tumor Research Group, Children's Cancer Study Group and Radiation Therapy Oncology Group. Previously she was the vice president of clinical development and operations at a number of pharmaceutical companies including Prometheus Laboratories and Shire.